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Abstract
Background: Non-vitamin K antagonist (VKA) oral anticoagulants (NOACs) have substantially improved anticoagulation
therapy for prevention of stroke and systemic embolism in patients with atrial fibrillation (AF). The available
routine care data have demonstrated the safety of different NOACs; however, such data for edoxaban are
scarce. Here, we report baseline characteristics of 13,638 edoxaban-treated patients with AF enrolled between
November 2016 and February 2018.
Methods: ETNA-AF-Europe is a multinational, multi-centre, post-authorisation, observational study conducted
in 825 sites in 10 European countries. Patients will be followed up for four years.
Results: Overall, 13,980 patients were enrolled of which 342 patients were excluded from the analysis. Mean
patient age was 73.6 years with an average creatinine clearance of 69.4 mL/min. 56.6% were male. The
calculated CHA2DS2-VASc and HAS-BLED mean scores were 3.1 and 2.6, respectively. Overall, 3.3, 14.6 and
82.0% of patients had low (CHA2DS2-VASc = 0), intermediate (CHA2DS2-VASc = 1) and high (CHA2DS2-VASc≥2)
risks of stroke, respectively. High-risk patients (those with prior stroke, prior major bleeding, prior intracranial
bleed or CHA2DS2-VASc ≥4) comprised 38.4% of the overall population. For 75.1% of patients edoxaban was
their first anticoagulant prescription, whilst 16.9% switched from a VKA and 8.0% from another NOAC. A total
of 23.4% of patients in ETNA-AF-Europe received the reduced dose of edoxaban 30 mg. Overall, 83.8% of
patients received an edoxaban dose in line with the criteria outlined in the label.
Conclusion: Edoxaban was predominantly initiated in older, often anticoagulation-naïve, unselected European
patients with AF, with a good overall adherence to the approved label.
Trial registration: NCT02944019; Date of registration: October 24, 2016.
Keywords: Non-vitamin K antagonist oral anticoagulants, Real-world, Registry, Stroke prevention, Major
bleeding, Safety outcomes
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: p.kirchhof@bham.ac.uk
14Institute of Cardiovascular Sciences, University of Birmingham, SWBH and
UHB NHS Trusts, IBR 136, Wolfson Drive, Birmingham B15 2TT, UK
15The Atrial Fibrillation NETwork (AFNET), Münster, Germany
Full list of author information is available at the end of the article
De Caterina et al. BMC Cardiovascular Disorders          (2019) 19:165 
https://doi.org/10.1186/s12872-019-1144-x
Background
Atrial fibrillation (AF) is the most prevalent sustained
cardiac arrhythmia, and a major cause of ischaemic
stroke and disabilities. AF is associated with increased
mortality and poses a high burden upon healthcare
resources [1]. The risk of strokes related to AF can be
substantially reduced through effective anticoagulation.
In recent years, non-vitamin K antagonist (VKA) oral
anticoagulants (NOACs) including the direct thrombin
inhibitor dabigatran and the direct factor Xa inhibitors
rivaroxaban, apixaban, and edoxaban, have greatly
improved anticoagulation therapy for the prevention of
stroke and systemic embolism in patients with AF.
Randomised controlled trials (RCTs) have shown that
these agents have at least similar efficacy compared to
VKAs, with improved safety, specifically with regards to
intracranial haemorrhage [2–6]. In the light of these
findings, the European Society of Cardiology 2016 guide-
lines recommend using NOACs in preference to VKAs
when oral anticoagulation is initiated in a patient eligible
for a NOAC [7].
Edoxaban, a highly selective, once-daily, direct, revers-
ible inhibitor of Factor Xa was approved for stroke pre-
vention in patients with AF in Europe in 2015, as well as
for the treatment and secondary prevention of venous
thromboembolism (VTE) in adults. The recommended
edoxaban dose is 60 mg once daily with a reduced dose
of 30 mg once daily for patients with moderate or severe
renal impairment (creatinine clearance 15–50mL/min),
low body weight (≤60 kg), or concomitant use of strong
p-glycoprotein inhibitors, including cyclosporine, drone-
darone, erythromycin, or ketoconazole [8].
The prescribing of NOACs has increased substantially
over the last few years. Recent, real world evidence
(RWE) studies have been enrolling patients with AF into
various registries such as GLORIA-AF [9], ORBIT AF-II
[10], XANTUS [11], GARFIELD-AF [12], DRESDEN
NOAC Registry [13], PREFER in AF [14], EORP-AF
Registry [15], Danish Registry [16] and retrospective
claims analyses [17–20]. These have demonstrated the
safety of different NOACs in routine clinical use. Since
edoxaban was the last of the four NOACs to enter the
market, published data on the use of edoxaban in
routine clinical practice are still limited compared with
other NOACs [16]. The objective of this analysis was to
describe the characteristics of unselected European pa-
tients with AF initiated on edoxaban, to compare these
characteristics with the European patients enrolled into
ENGAGE AF-TIMI 48, and to describe adherence to the
dosing recommendations for edoxaban.
Methods
The Edoxaban Treatment in Routine Clinical Practice for
Patients With Non Valvular Atrial Fibrillation (ETNA-AF-
Europe) was designed as part of the risk management plan
of edoxaban in order to assess the risks and benefits of the
drug in routine care in unselected European patients with
AF. ETNA-AF-Europe is part of the global ETNA initia-
tive, which is composed of separate, non-interventional
prospective ETNA-AF registries in Europe, East Asia,
Brazil and Japan. The final ETNA-AF-Europe protocol
was developed based on discussions with, and finally
approved by the Pharmacovigilance Risk Assessment
Committee (PRAC) of the European Medicines Agency.
The primary objective of ETNA-AF Europe is to assess
the safety of edoxaban by evaluating bleeding events,
including intracranial haemorrhage; drug related adverse
events, such as liver adverse events; and cardiovascular
(CV) as well as all-cause mortality in routine care patients
with AF treated with edoxaban up to 4 years, with regard
to onset (relative to treatment with edoxaban) of the
event, duration, severity and outcomes.
Details of the design of ETNA-AF-Europe including
the statistical rationale have been published [21]. In
short, ETNA-AF-Europe is a multinational, multi-centre,
post-authorisation, observational study (Clinicaltrials.gov:
NCT02944019) conducted in 825 sites (with at least one
patient enrolled) in 10 European countries. All patients
with non-valvular AF treated with edoxaban according to
the summary of product characteristics (SmPC), could
participate in the study with prior provision of written
informed consent and no simultaneous participation in an
interventional trial. No explicit exclusion criteria were
defined. Over a period of 3 years, ETNA-AF-Europe en-
rolled 13,980 patients with AF confirmed within the last
12months before enrolment. AF had to be confirmed by
the investigators by electrical tracing (e.g., ECG, Holter
monitoring, pacemaker or other implantable device). De-
tailed information on AF history and diagnosis, and on
previous AF-related therapies was collected, including
former anticoagulant treatment with VKAs, NOACs or
heparins; previous or current antiplatelet drugs, antiar-
rhythmic and rate-control drugs and other therapies. The
CHA2DS2-VASc and HAS-BLED scores were both re-
ported by the investigators as well as calculated based on
the baseline clinical characteristics of the patients. For the
analysis here reported, calculated scores are used. Specific
subgroup analyses are planned by edoxaban dose, patient
age and country. Figure 1 provides an overview of the
patient disposition in ETNA-AF-Europe. Of 13,980
enrolled patients, 13,638 were included in the baseline
analysis set. Patients are to be followed up once a year for
a total of 4 years.
The patient baseline characteristics from ENGAGE
AF-TIMI 48 are used as an external comparator to the
baseline data collected in ETNA-AF-Europe to better
understand how the usage of edoxaban in routine
clinical practice reflects on the trial setting in which
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edoxaban was tested. The ENGAGE AF-TIMI 48 cohort
used for this purpose includes patients from only those
European countries that are also participating in the
ETNA-AF-Europe registry.
Results
Baseline characteristics
A total of 13,980 patients were enrolled between No-
vember 2016 and February 2018 of which 342 patients
were excluded from the analysis because they were miss-
ing baseline data, missing information on edoxaban
treatment at baseline, not fulfilling the regional eligibility
criteria, receiving doses other than 60 or 30mg and
other reasons (Fig. 1). Of those, 13,638 patients were
evaluated in the analysis of demographics and other
baseline characteristics (Fig. 1). The baseline demo-
graphics and clinical characteristics of the entire analysis
set as well as for the edoxaban 60mg and 30 mg dose
groups separately, are summarised in Table 1. Per-
country split of the number of patients was as follows:
Austria (n = 295 [2.2%]), Belgium (n = 1315 [9.6%]),
Germany (n = 5288 [38.8%]), Ireland (n = 168 [1.2%]),
Italy (n = 3509 [25.7%]), The Netherlands (n = 1263
[9.3%]), Portugal (n = 108 [0.8%]), Spain (n = 838 [6.1%]),
Switzerland (n = 156 [1.1%]) and United Kingdom
(n = 698 [5.1%]) (Fig. 2).
The mean (SD) patient age was 73.6 ± 9.52 years (inter-
quartile range Q1–Q3: 68.0–80.0 years) with an average
creatinine clearance (CrCl) of 69.4 mL/min as calculated
according to the Cockroft-Gault equation, and 7718
(56.6%) of the patients were male. The mean (SD) body
weight was 81.0 ± 17.34 kg and mean (SD) body mass
index was 28.1 ± 5.14 kg/m2. Mean CHA2DS2-VASc and
HAS-BLED scores were 3.3 ± 1.45 and 1.9 ± 1.02 as re-
ported by the investigators, respectively. In contrast, the
calculated CHA2DS2-VASc and HAS-BLED mean scores
were 3.1 ± 1.40 and 2.6 ± 1.13, respectively. Overall, 452
(3.3%) of patients had a CHA2DS2-VASc score of 0;
1997 (14.6%) of patients had a CHA2DS2-VASc of 1 and
11,186 (82.0%) of patients had a CHA2DS2-VASc score
of ≥2 (defined according to ESC guidelines [7] (Fig. 3).
The first diagnosis of AF had been made over two years
before enrolment (mean [Q1–Q3]: 25.7 [29.3–0.4]
months) (Table 1). Just over half of the patient popula-
tion presented with paroxysmal AF, and 19.6% of the pa-
tients presented with permanent AF. Hypertension was
the most common cardiovascular comorbidity (76.9%),
followed by valvular heart disease (17.7%) and heart fail-
ure (5.8%) (Table 1). Patients with a previous ischaemic
stroke accounted for 5.9%, transient ischaemic attack
3.3, and 4.3% had a prior myocardial infarction. A prior
bleeding event was found in 3.1% of patients (Table 1).
Fig. 1 Overview of the ETNA-AF-Europe registry. *Some patients fulfilled more than one exclusion criteria
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Overall, 10,242 (75.1%) patients were not on anticoa-
gulation prior to initiating edoxaban, whilst 2305 (16.9%)
switched from a VKA (Fig. 4): 904 (39.2%) from warfarin,
732 (31.8%) from acenocumarol and 658 (28.5%) from
phenprocoumon. Furthermore, 1091 (8.0%) switched
from another NOAC: 341 (31.3%) from apixaban, 283
(25.9%) from dabigatran and 453 (41.5%) from rivaroxa-
ban and 14 (1.3%) from others (not specified).
Table 1 Baseline demographics and clinical characteristics of
patients included in ETNA-AF-Europe
Characteristic Total Edoxaban
60mg OD
Edoxaban
30 mg OD
Patients, N (%) 13,638 (100) 10,444 (76.6) 3194 (23.4)
Male, % 56.6 60.6 43.5
Age, years, mean (SD) 73.6 (9.52) 71.8 (9.23) 79.6 (7.87)
By age sub-groups, %
< 65 years 15.4 18.8 4.1
65–74 years 33.7 38.5 18.0
75–84 years 40.3 37.3 50.4
≥ 85 years 10.6 5.4 27.5
Body weight, kg, mean (SD) 81.0 (17.34) 83.5 (16.77) 72.8 (16.63)
BMI, kg/m2, mean (SD) 28.1 (5.14) 28.6 (5.06) 26.5 (5.07)
SBP, mmHg, mean (SD) 133.4 (18.04) 133.7 (17.90) 132.6 (18.46)
DBP, mmHg, mean (SD) 78.3 (10.90) 79.0 (10.91) 76.2 (10.60)
Current smoking, % 6.3 6.9 4.4
Alcohol, %
No 44.8 42.0 54.0
CrCl (reported), mL/min,
mean (SD)
69.4 (24.23) 75.5 (22.65) 50.8 (18.90)
By CrCl subgroups, %
< 15 0.6 0.7 0.2
(15, 30) 1.9 0.3 6.8
(30, 50) 18.0 6.7 52.9
(50, 80) 48.2 53.6 31.6
≥ 80 31.3 38.7 8.5
Patients with dose reduction criteria, %
Body weight≤ 60 kg, % 10.4 5.0 27.6
CrCl 15–50mL/min, % 19.9 7.0 59.7
Concomitant use of P-gp
inhibitorsa, %
1.0 0.9 1.5
(calc.) CHADS2, mean (SD) 1.7 (1.07) 1.6 (1.05) 2.1 (1.03)
(calc.) CHA2DS2-VASc, mean
(SD)
3.1 (1.40) 2.9 (1.37) 3.8 (1.26)
CHASDS2-VASc score = 0, % 2.3 2.8 0.3
CHASDS2-VASc score = 1, % 10.3 12.6 2.5
(calc.) HAS-BLED, mean 2.6 (1.13) 2.4 (1.11) 3.0 (1.10)
Frailtyb, %
Yes 10.6 6.1 25.3
No 82.7 87.3 67.4
Not known 6.7 6.6 7.3
Previous history of CV disease, %
Hypertension 76.9 75.9 80.0
Congestive heart failure 5.8 4.7 9.5
Myocardial infarction 4.3 3.7 6.2
Angina pectoris 1.5 1.3 2.1
Valvular disease 17.7 16.2 22.9
Table 1 Baseline demographics and clinical characteristics of
patients included in ETNA-AF-Europe (Continued)
Characteristic Total Edoxaban
60mg OD
Edoxaban
30 mg OD
Peripheral artery disease 3.3 2.8 5.2
Previous history of diabetes
mellitus, %
21.9 20.5 26.7
Previous history of stroke and ICH, %
Ischaemic stroke 5.9 5.6 6.9
Stroke, unknown 0.6 0.5 0.8
Transient ischaemic attack 3.3 3.2 3.7
Intracranial haemorrhage 0.5 0.4 0.6
Previous history of bleeding, %
Any bleeding 3.1 2.5 5.2
GI bleeding (Major or
CRNM)
0.8 0.5 1.7
Major 1.0 0.8 1.6
CRNM 1.0 0.8 1.8
Minor 1.1 0.9 1.8
Renal disease (including
dialysis), %
27.0 19.5 51.6
Current AF type, %
Paroxysmal 53.6 54.5 50.4
Persistent 24.4 25.3 21.2
Long-standing persistent 2.4 2.3 2.9
Permanent 19.6 17.8 25.5
Time since first AF diagnosis, months
Mean (SD) 25.7 (46.88) 24.9 (47.01) 28.4 (46.37)
IQ, Q1–Q3 29.3–0.4 26.5–0.4 37.5–0.6
Previous use of AF relevant medication, %
VKA 16.9 16.3 18.9
NOAC (other) 8.0 6.9 11.6
Antiarrrhythmics 5.0 5.0 4.8
Antiplatelet 15.1 14.8 16.2
a P-gp inhibitors requiring edoxaban dose reduction: cyclosporine,
dronedarone, erythromycin, ketoconazole
b There was no specific definition for frailty; it was left to the discretion of the
physician to categorise a patient as frail
AF atrial fibrillation, BMI body mass index, CKD chronic kidney disease, CrCl
creatinine clearance, CRNM clinically relevant non-major, CV cardiovascular,
DBP diastolic blood pressure, GI gastrointestinal, ICH intracranial haemorrhage, IQ
interquartile range, NOAC non-vitamin K antagonist oral anticoagulant, NSAIDs
non-steroidal anti-inflammatory drugs, OD once daily, P-gp P-glycoprotein, SBP
systolic blood pressure, SD standard deviation, VKA vitamin K antagonist
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Of the 13,638 patients, 10,444 (76.6%) received edoxa-
ban 60mg and 3194 (23.4%) received 30mg once daily.
Adherence to the edoxaban SmPC was 83.8%, with 11,
432/13,638 patients being dosed in line with the edox-
aban label. Of the 2206 patients (16.2%) not dosed
following the label, 1031 patients (7.5%) received 30
mg edoxaban without the criteria for dose reduction,
whereas 1175 patients (8.6%) received edoxaban 60
mg even though at least one of the dose reduction
criteria was present.
Fig. 2 Number of patients per region (by dose) in the European ETNA-AF registry. BeNeLux, Belgium, the Netherlands, and Luxembourg; DACH,
Germany, Austria, Switzerland
a
b
Fig. 3 Mean CHA2DS2-VASc and HAS-BLED [calculated] score distribution by dose groups. a CHA2DS2-VASc score distribution
(7): Low risk: Score = 0 for
men, 1 for women. Intermediate risk: Score = 1 for men, 2 for women. High risk: Score≥ 2 for men, > 2 for women. b HAS-BLED score distribution: Low
risk: Score < 2. Intermediate risk: Score 2–3. High risk: Score≥ 4
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There were considerable differences in the characteris-
tics of patients receiving the 60mg vs the 30 mg dose.
The mean baseline CrCl was 75.5 mL/min and 50.8 mL/
min for the edoxaban 60 mg and 30 mg dose groups,
respectively. 60.2% of patients in the edoxaban 30 mg
dose group, compared to only 8.3% in the edoxaban 60
mg group, had a baseline CrCl of ≤50ml/min (Fig. 5). A
history of chronic kidney disease was reported in 19.5
and 51.6% of patients receiving edoxaban 60mg and 30
mg doses, respectively.
High-risk patients, defined in the ETNA-AF-Europe
registry as patients with a high risk for either stroke
or bleeding based on presence of either a prior
stroke, prior major bleeding or prior ICH, or a
CHA2DS2-VASc score ≥ 4, comprised 38.4% of the
overall population; with 32.1 and 58.9% of those re-
ceiving edoxaban 60 mg and 30 mg doses, respectively
categorised as high-risk patients (Fig. 6). Overall,
1442 (10.6%) of patients were considered frail, more
than half of those were receiving edoxaban 30 mg
once daily. There was no specific definition for frailty;
it was left to the discretion of the physician to cat-
egorise a patient as frail.
A large majority of patients (77.8%) receiving edoxa-
ban 30 mg versus 42.7% of patients on edoxaban 60 mg
were aged ≥75 years. CHA2DS2-VASc scores ≥4 were
more frequent in patients receiving edoxaban 30 mg
(58.2%) versus edoxaban 60 mg dose (31%) (Fig. 3).
A greater proportion of patients with a previous
history of CV disease received edoxaban 30mg as
compared with edoxaban 60mg dose. Ischaemic stroke
was reported in 6.9% versus 5.6% in the edoxaban 30mg
versus 60 mg dose group and myocardial infarction in
6.2% versus 3.7%, respectively (Table 1). Likewise, a his-
tory of any bleeding was documented more frequently
for the edoxaban 30 mg versus edoxaban 60 mg dose
(5.2% versus 2.5%, respectively).
Discussion
The baseline characteristics of the ETNA-AF-Europe
registry here reported indicate that among the 13,980
patients enrolled, there is a consistent percentage of
Fig. 4 Percentage of patients who received antithrombotic or antiarrhythmic treatment prior to enrolment. AF, atrial fibrillation; BL, baseline;
NOAC, non-vitamin K antagonist oral anticoagulant; VKA, vitamin K antagonist
Fig. 5 The stages of chronic kidney disease [calculated, Cockroft Gault] at baseline by dose groups
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elderly patients, with 50.9% of them ≥75 years of age.
Most enrolled patients are naïve to prior anticoagulation
(75.1%) and more than half have paroxysmal AF (53.6%).
The use of the 60 mg full dose is overall predominant
(76.6%), but among the high risk and frail patients, the
use of 30 mg is higher (58.9 and 56%, respectively). For
randomisation in ENGAGE AF-TIMI 48, a CHADS2
score of 2 or more was required, whereas the approved
European Medicines Agency label requires only a
CHADS2 score of 1 to be eligible for treatment with edox-
aban. Daiichi Sankyo, the ETNA-AF steering committee
and the European Medicines Agency have therefore jointly
designed the ETNA-AF-Europe study to provide import-
ant additional safety information on the use of edoxaban
in routine care.
The baseline demographics and clinical characteristics
of patients receiving edoxaban in ETNA-AF-Europe
were broadly similar to those enrolled in the European
cohort of the ENGAGE AF-TIMI 48 trial, yet there were
some notable differences (Table 2). The mean CHADS2
and CHA2DS2-VASc scores were considerably lower in
the ETNA-AF-Europe registry compared with the EN-
GAGE AF-TIMI trial (CHADS2: 1.7 versus 2.8 and
CHA2DS2-VASc: 3.1 versus 4.2, respectively) and patients
more frequently presented with paroxysmal AF (53.6%
versus 26.6%, respectively) (Table 2). The lower mean
CHADS2 score in ETNA-AF-Europe likely reflected the
difference between the European label of edoxaban
(CHADS2 ≥ 1) and the inclusion criteria of ENGAGE AF-
TIMI 48 (a score of 2 or higher on the CHADS2 risk
assessment), and may also hint to a cautious approach of
prescribing physicians to newly marketed medicines.
In keeping with the different inclusion criteria, cardio-
vascular comorbidities such as hypertension, congestive
heart failure and history of ischaemic stroke were more
common in patients in the European ENGAGE AF-
TIMI 48 trial versus those included in ETNA-AF-
Europe. Also, prior CV events such as ischaemic stroke
and transient ischaemic attack were fewer in ETNA-AF-
Europe versus the ENGAGE AF-TIMI 48 trial.
There are important markers of high risk of complica-
tions in the ETNA-AF-Europe population. Patients re-
ceiving edoxaban in routine care are slightly older than
those enrolled in the ENGAGE AF-TIMI 48 trial. The
population in the ETNA-AF-Europe analysis had a
higher bleeding risk than those recorded in the corre-
sponding countries in ENGAGE AF-TIMI 48, with mean
HAS-BLED scores of 2.5 and 1.6 in ETNA-AF-Europe
and ENGAGE AF-TIMI 48, respectively (Table 2). The
ETNA-AF-Europe population shows a slightly lower cre-
atinine clearance and a higher proportion of patients
with chronic kidney disease (Table 2). These findings
underpin the general assumption that patients at a
higher risk are under-represented in phase III trials, in-
cluding those of anticoagulants for stroke prevention in
AF.
In ETNA-AF-Europe, the mean investigator-reported
CHA2DS2-VASc score was higher than the formally cal-
culated score whereas the mean investigator reported
HAS-BLED score was lower than the formally calculated
score. These findings suggest that physicians may have
overestimated the risk of stroke and underestimated the
risk of bleeding in the ETNA-AF-Europe population.
Specifically, the HAS-BLED score may potentially not be
widely used in daily clinical practice so the physicians’
lack of familiarity with this score could have played a
role in the underestimation of bleeding risk. Further in-
vestigations in the ETNA-AF-Europe database for the
potential reasons related to a wrong perception of risks
such as consideration of specific comorbidities or patient
history may bring more clarity to this finding. For now,
this finding highlights the continued need for educating
health care professionals and patients in Europe con-
cerning anticoagulation [22].
Fig. 6 Difficult-to-treat patients at baseline categorised by dose groups. *A patient is considered as a high risk patient if he/she has at least one
of the following: prior stroke, prior major bleeding, prior ICH or (calculated) CHA2DS2-VASc ≥4.
†There was no specific definition for frailty; it was
left to the discretion of the physician to categorise a patient as frail
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In routine clinical practice, it is commonly observed
that NOACs are frequently prescribed at a lower dose
despite not meeting the dose reduction criteria listed in
the label [23, 24]. Therefore, compared with the pivotal
clinical trials, the use of reduced NOAC doses in daily
clinical practice appears to be more frequent [25, 26]. A
retrospective study reported the use of a reduced dose of
NOACs in 56.8% of patients with no clear indication,
and use of non-reduced dose in 43.2% of patients while
indicated [25]. Such findings suggest the need to
strengthen dosing education of NOACs in clinical prac-
tice. Notably, the distribution of the edoxaban 60 mg
and 30 mg dosing in ETNA-AF-Europe was largely in
line with the distribution within corresponding countries
from ENGAGE AF-TIMI 48; a total of 23.4% of patients
in ETNA-AF-Europe received the reduced dose of edox-
aban 30mg which was similar to the percentage of
patients (21.8%) eligible for dose reduction in the
European cohort of the ENGAGE AF-TIMI 48 trial.
Among the edoxaban dose reduction criteria listed in
the SmPC, reduced renal clearance ≤50ml/min is by far
the most frequently applied criterion in a Western popu-
lation [27], whereas low body weight (below 60 kg) or
concomitant use of certain P-gp-inhibitors are less often
met. The ETNA programme will provide information on
patients characteristics in other parts of the world,
where weight < 60 kg may be more common.
Since poor renal function is associated with old age
and various comorbidities, the differences in baseline
characteristics of patients receiving edoxaban 30 mg and
60mg groups are broadly in line with expectations.
History of congestive heart failure, myocardial infarction,
angina pectoris and valvular heart disease was more
commonly observed in the 30mg dose group as
compared with the patients receiving the 60 mg dose
(Table 1). High risk patients, predefined as those with
prior stroke, prior major bleed, prior intracranial haem-
orrhage, or CHA2DS2-VASc score ≥ 4 accounted for
38.4% of patients in ETNA-AF and a higher proportion
of these difficult-to-treat patients received the edoxaban
30mg dose versus edoxaban 60 mg dose in ETNA-AF-
Europe. The same was true for patients considered frail
by the investigator.
In ETNA-AF-Europe, a high adherence of 83.8% to
the dose selection criteria according to the SmPC was
observed. The consistent dosing criteria for edoxaban
across all indications may have contributed to this find-
ing. Nevertheless, not all patients were dosed according
to the label; approximately 16% of patients received a
dose that was not in line with the SmPC, with 7.5% (n =
1031) of patients receiving edoxaban 30 mg instead of
the recommended 60 mg, and 8.6% (n = 1175) of patients
receiving 60mg instead of the recommended 30 mg. The
rationale for prescribing the 60mg dose despite the
presence of a dose reduction criterion is currently
unclear and needs further analyses. The general overesti-
mation of the CHA2DS2-VASc score combined with the
underestimation of the HAS-BLED score by the ETNA-
AF-Europe investigators or unavailability of renal func-
tion at the time of prescribing, may both have played a
role in this context. Future analyses on specific charac-
teristics of these patients such as very high body weight
or certain co-morbidities are warranted. Furthermore,
patient age, creatinine clearance or body weight close to
the indicated dose reduction threshold, or the fear of
iatrogenic bleeding in a fragile patient population that
already had a frequent history of bleeding may have
Table 2 Comparison of baseline characteristics of patients in
the ETNA-AF-Europe registry and ENGAGE AF-TIMI 48 trial
ETNA-AF-Europe
N = 13,638
ENGAGE AF-TIMI
48a Corresponding
ETNA-AF countriesb
N = 2123
Age (y), mean (SD) 73.6 (9.52) 72.7 (8.09)
By age sub-groups, n (%)
< 65 years 2096 (15.4) 344 (16.2)
65–75 years 4598 (33.7) 764 (36.0)
≥ 75 years 6939 (50.9) 1015 (47.8)
Male, % 56.6 62.4
BMI (kg/m2), mean (SD) 28.1 (5.14) 29.8 (5.39)
Weight (kg), mean (SD) 81.0 (17.34) 85.4 (17.47)
eCrCl (mL/min), mean (SD) 69.4 (24.23) 75.5 (28.96)
CHADS2, mean (SD) 1.7 (1.07) 2.8 (0.93)
CHA2DS2-VASc, calculated,
mean (SD)
3.1 (1.40) 4.2 (1.31)
HAS-BLED, mean (SD) 2.6 (1.13) 1.6 (0.92)
Hypertension, % 76.9 92.4
Diabetes, % 21.9 39.1
Myocardial infarction, % 4.3 2.9
Ischaemic stroke, % 5.9 15.5
Transient ischaemic attack, % 3.3 11.9
Congestive heart failure, % 5.8 48.2
Paroxysmal AF, % 53.6 26.6
Persistent AF, % 24.4 24.1
Permanent AF, % 19.6 49.4
Renal disease (including
dialysis), %
27.0 11.9
amITT
bBelgium, Switzerland, Germany, Spain, United Kingdom, Italy, Netherlands, Portugal
% values are based on non-missing data
AF atrial fibrillation, BMI body mass index, CHADS2 Congestive heart failure,
Hypertension, Age ≥ 75 years, Diabetes mellitus, Stroke (double weight), eCrCl
estimated creatinine clearance (Cockcroft-Gault), ENGAGE AF-TIMI 48 study
Effective aNticoaGulAtion with Factor Xa next GEneration in Atrial Fibrillation-
Thrombolysis In Myocardial Infarction study 48, ETNA-AF Edoxaban Treatment in
routine cliNical prActice, mITT modified intent-to-treat, SD standard deviation
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contributed to the choice of the lower edoxaban dose
deviating from the label. In support, perceived frailty of
patients was more frequently reported in patients receiv-
ing the 30 mg dose (Fig. 6), which could have influenced
the prescribing pattern independent of the criteria in the
label. Publications such as the 2018 European Heart
Rhythm Association Practical Guide [28] have certainly
helped in raising awareness regarding the need for ap-
propriate dosing of NOACs. The details in the EHRA
guide differ somewhat from the criteria outlined in the
SmPC. It will be interesting to apply these additional cri-
teria to the ETNA-AF-Europe population and this study
provides an opportunity to look into this.
It is widely accepted that randomised trials are the
gold standard for ascertaining the efficacy and safety of a
given therapy. However, RCTs are not fully representa-
tive of an unselected real-world population due to their
highly controlled settings. For example, in all phase 3 AF
NOAC trials, patients with very high bleeding risk were
largely excluded, resulting in paucity of data on these
patients. In addition, the patient population specified in
the label is usually broader than the key inclusion cri-
teria of the pivotal trials. On the other hand, a prospect-
ive registry might also have limitations, due to the lack
of randomisation: physicians might tend to prescribe a
certain therapy to a specific category of patients, and
furthermore patients could opt in for enrolment. These
features might cause a selection bias that may hamper
the generalizability of the observed results.
In our registry, the majority of AF patients were
anticoagulation-naïve prior to the initiation of edoxaban.
Patients were also reported to switch from another
NOAC to edoxaban, illustrating a clinical need for more
than one NOAC for stroke prevention in AF. The recent
registry data have shown that 95% of edoxaban users en-
rolled via the Danish National Prescription Registry [16]
had previously received some anticoagulant treatment,
with 77% switching directly from another anticoagulant
treatment to edoxaban (45% from VKA and 32% from
other NOACs). In this registry, users of edoxaban were
comparable with users of other NOACs, with a median
age of 75 versus 72–76 years and 57% versus 53–59%
males. These baseline results are the first consistent
evidence of real-world use of once daily edoxaban, the
most recently approved NOAC, in Europe.
Conclusion
Edoxaban is predominantly used in routine clinical prac-
tice for older AF patients, mostly anticoagulation-naïve
with dosing in line with recommendations in the ap-
proved European Union label for a high proportion of
patients (84%). The patient population enrolled in
ETNA-AF-Europe is similar to those enrolled in the
ENGAGE AF TIMI-48 trial and showed a similar
proportional usage of the reduced 30mg edoxaban dose.
Differences between the populations include slightly
higher age, more patients with paroxysmal AF, lower
CHA2DS2-VASc score, higher bleeding risk, less cardio-
vascular comorbidities and more renal impairment in
ETNA-AF-Europe.
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